TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 66.1%

Neg 0% Neu 0% Pos 66.1%

TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $50 to $55.